Hans T. Scambye joins Sunstone as Venture Partner

Hans T. Scambye joins Sunstone as Venture Partner Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics secures euro 20M in Series A financing Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round...